L-alpha-谷氨酰-L-蛋氨酸 | 4423-22-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: L-alpha-谷氨酰-L-蛋氨酸
• 英文名称: Glu-Met
• 英文别名: (4S)-4-amino-5-[[(1S)-1-carboxy-3-methylsulfanylpropyl]amino]-5-oxopentanoic acid
• CAS: 4423-22-7
• 化学式: C₁₀H₁₈N₂O₅S
• 分子量: 278.33
• InChiKey: SXGAGTVDWKQYCX-BQBZGAKWSA-N

物化性质

• 熔点：
  163-166 °C
• 沸点：
  627.5±55.0 °C(Predicted)
• 密度：
  1.343±0.06 g/cm3(Predicted)
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  -3.7
• 重原子数：
  18
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  155
• 氢给体数：
  4
• 氢受体数：
  7

安全信息

• 海关编码：
  2930909090

文献信息

• ONION EXTRACT, AND PROCESS FOR PRODUCTION THEREOF
  申请人：Takasago International Corporation

  公开号：EP2454950A1

  公开（公告）日：2012-05-23

  An onion extract which contains glutamylmethionine, quercetin and protocatechuic acid, wherein a weight ratio of the quercetin to the glutamylmethionine (quercetin/glutamylmethionine) is 0 to 0.49, and a weight ratio of the protocatechuic acid to the glutamylmethionine (protocatechuic acid/glutamylmethionine) is 0 to 1.86.

  一种含有谷氨酰基蛋氨酸、槲皮素和原儿茶酸的洋葱提取物，其中槲皮素与谷氨酰基蛋氨酸的重量比（槲皮素/谷氨酰基蛋氨酸）为 0 至 0.49，原儿茶酸与谷氨酰基蛋氨酸的重量比（原儿茶酸/谷氨酰基蛋氨酸）为 0 至 1.86。
• Biomarkers for cardiovascular diseases and methods using the same
  申请人：Metabolon, Inc.

  公开号：US10175233B2

  公开（公告）日：2019-01-08

  Biomarkers relating to cardiovascular disease, including atherosclerosis and cardiomyopathy, are provided, as well as methods for using such biomarkers as biomarkers for cardiovascular disease. In addition, methods for modulating the respective disorders or conditions of a subject are also provided. Also provided are suites of small molecule entities as biomarkers for cardiovascular disease, including atherosclerosis and cardiomyopathy.

  本研究提供了与心血管疾病（包括动脉粥样硬化和心肌病）有关的生物标志物，以及将此类生物标志物用作心血管疾病生物标志物的方法。此外，还提供了调节受试者相应疾病或状况的方法。还提供了作为心血管疾病（包括动脉粥样硬化和心肌病）生物标志物的成套小分子实体。
• Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment
  申请人：Metabolon, Inc.

  公开号：US10267777B2

  公开（公告）日：2019-04-23

  Methods are described herein for small molecule biochemical profiling of an individual subject for diagnosis of a disease or disorder, facilitating diagnosis of a disease or disorder, and/or identifying an increased risk of developing a disease or disorder in the individual subject. Aberrant levels of small molecules present in a sample from an individual subject are identified and diagnostic information relevant to the individual subject is obtained based on the identified aberrant levels. The obtained diagnostic information includes one or more of an identification of at least one biochemical pathway associated with the identified subset of the small molecules having aberrant levels, an identification at least one disease or disorder associated with the identified subset of the small molecules having aberrant levels, and an identification of at least one recommended follow up test associated with the identified subset of the small molecules having aberrant levels.

  本文描述了对个体受试者进行小分子生化分析的方法，以诊断疾病或失调，促进疾病或失调的诊断，和/或确定个体受试者罹患疾病或失调的风险增加。确定个体受试者样本中存在的小分子的异常水平，并根据确定的异常水平获得与个体受试者相关的诊断信息。所获得的诊断信息包括：至少一个生化途径的鉴定，该生化途径与所鉴定的具有异常水平的小分子子集相关；至少一种疾病或紊乱的鉴定，该疾病或紊乱与所鉴定的具有异常水平的小分子子集相关；至少一种推荐的后续检测的鉴定，该检测与所鉴定的具有异常水平的小分子子集相关。
• Mutant protein having the peptide-synthesizing activity
  申请人：Takeshita Rie

  公开号：US20060188976A1

  公开（公告）日：2006-08-24

  The present invention is to provide an excellent peptide-synthesizing protein and a method for efficiently producing a peptide. A peptide is synthesized by reacting an amine component and a carboxy component in the presence of at least one of proteins shown in the following (I) and (II): (I) The mutant protein having the amino acid sequence containing one or more mutations of the above mutations 1 to 38 in the amino acid sequence described in SEQ ID NO:2; and (II) The mutant protein having the amino acid sequence containing one or more mutations selected from the group consisting of substitution, deletion, insertion, addition and inversion at positions other than one or more mutation positions of the above mutation 1 to 38 in the mutant protein described in the above (I), and having a peptide-synthesizing activity.

  本发明旨在提供一种优良的多肽合成蛋白和一种高效生产多肽的方法。肽的合成是通过胺组分和羧基组分在以下(I)和(II)所示蛋白质中的至少一种存在下发生反应来实现的：(I)突变体蛋白质，其氨基酸序列含有 SEQ ID NO.2 所述氨基酸序列中上述突变 1 至 38 中的一个或多个突变；以及(II)突变体蛋白质，其氨基酸序列含有 SEQ ID NO.2 所述氨基酸序列中上述突变 1 至 38 中的一个或多个突变：2中所述氨基酸序列中含有上述突变1至38中的一个或多个突变位置以外的一个或多个突变的氨基酸序列的突变体蛋白质；以及(II)在上述(I)中所述突变体蛋白质中，在上述突变1至38中的一个或多个突变位置以外的位置上含有选自由取代、缺失、插入、添加和反转组成的组中的一个或多个突变的氨基酸序列，并具有肽合成活性的突变体蛋白质。
• METABOLOMIC PROFILING DEFINES ONCOGENES DRIVING PROSTATE TUMORS
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：EP2929352A1

  公开（公告）日：2015-10-14